

AP20 Rec'd PCT/PTO 28 APR 2006

PROCESSES FOR THE PREPARATION OF CEPHALOSPORIN DERIVATIVES**TECHNICAL FIELD**

5 The present invention relates to a process for preparing cephalosporin derivatives, including cefprozil and its salt, using a 3-(Z)-propenyl cephem derivative stereospecifically prepared.

BACKGROUND ART

10 3-(Z)-propenyl cephem derivative is a compound useful as an intermediate for preparation of cefprozil which is an oral cephalosporin antibiotic. Various preparation processes thereof have been known.

WO93/16084 discloses a process for selectively separating a 3-(Z)-propenyl cephem compound by means of a hydrochloride, metal, or tertiary amine salt of
15 7-amino-3-(1-propen-1-yl)-3-cephem-carboxylic acid or by adsorption chromatography.

However, there is a disadvantage in that separation and purification are cost-ineffective.

U.K. Patent No. 2,135,305 discloses a process for preparing cefprozil from a 4-hydroxyphenylglycine compound with a t-butoxycarbonyl-protected amino group and
20 a cephem compound with a benzhydryl-protected carboxyl group. However, incorporation of a 3-propenyl group after acylation lowers reaction efficiency and high-performance liquid chromatography is required for isomer separation, which render industrial application difficult.

U.S. Patent No. 4,727,070 discloses a technique of removing an E-isomer
25 cefprozil from a mixture of Z/E cefprozil, which includes incorporating an active group such as sodium imidazolidinone into the mixture of Z/E cefprozil by reaction of the mixture of Z/E cefprozil with acetone, followed by deprotection. However, purification by chromatography incurs enormous costs.

In view of the above problems, Korean Patent Laid-Open Publication No.
30 2002-80838 discloses a process for preparing a 3-(Z)-propenyl cephem compound by reacting a phosphoranylidene cephem compound with acetaldehyde in a mixed solvent essentially consisting of ether in the presence of a base. According to a disclosure in this patent document, ether is essentially used. In this respect, in the case of using

methylenedichloride, tetrahydrofuran, etc., even when other reaction conditions, for example, reaction temperature, reaction duration, base, catalyst, and the like are adjusted, it is very difficult to adjust the content of the Z-isomer to more than 83%.

Korean Patent Laid-Open Publication No. 2002-69437 discloses a 4-hydroxyphenylglycine anhydride with a pivaloyl group, which is a compound useful as an intermediate for the 7-position of cefprozil, and a preparation process thereof.

DETAILED DESCRIPTION OF THE INVENTION

Technical Goal of the Invention


The present invention provides a process for simply preparing a cephalosporin antibiotic in high yield and purity using a 3-(Z)-propenyl cephem derivative stereospecifically prepared.

Therefore, the present invention provides a process for preparing a cephalosporin compound using a 3-(Z)-propenyl cephem derivative.


Disclosure of the Invention

According to an aspect of the present invention, there is provided a process for preparing a compound represented by the following formula 1 or its salt, which includes: reacting a compound represented by the following formula 4 with acetaldehyde in a mixed solvent including water, isopropanol, and methylenedichloride in a volume ratio of 1:3-6:11-14 in the presence of a first base to stereospecifically prepare a compound represented by the following formulae 3 and reacting the compound of the formula 3 with an anhydrous compound represented by the following formula 2 in the presence of a second base:


<Formula 1>




<Formula 2>



<Formula 3>



<Formula 4>



5 wherein R^1 is a hydrogen or an amino protecting group, R^2 is a hydrogen or a carboxyl protecting group, and R^3 is a hydrogen or an amino protecting group.

The salt of the compound of the formula 1 refers to a salt commonly known in the field of cephalosporin antibiotics, for example a hydrate or an acid addition salt.

As used herein, the term "stereospecific compound" refers to a mixed
10 compound (e.g., compound of the formula 1 or 3) composed of a Z-isomer (or cis-isomer) and an E-isomer (or a trans-isomer) in a ratio of about 89-94% to about 6-11%, i.e., a compound composed of a Z-isomer and an E-isomer in a ratio of about 8.1-15.7:1.0. In this respect, the term "stereospecific preparation process" refers to a process for preparing the "stereospecific compound".

15 The carboxyl protecting group and the amino protecting group may be protecting groups commonly used in synthesis of cephalosporin antibiotics. Examples of the carboxyl protecting group include allyl, benzyl, p-methoxybenzyl, p-nitrobenzyl, triphenylmethyl, and diphenylmethyl, and examples of the amino protecting group include 4-methoxybenzyl, formyl, acetyl, benzyl, benzylidene, diphenylmethyl,
20 triphenylmethyl, trichloroethoxycarbonyl, t-butoxycarbonyl, methylacetoacetate, ethylacetoacetate, and 2-ethoxycarbonyl-1-methylvinyl. Preferably, the carboxyl protecting group of R^2 and the amino protecting group of R^3 are respectively 4-methoxybenzyl and benzylcarbonyl which are commercially available. Preferably, the amino protecting group of R^1 is a protecting group that can be easily removed in the
25 presence of an acid.


According to the preparation process of the present invention, when the reaction is performed in the mixed solvent including water, isopropanol, and methylenechloride in a volume ratio of 1:3-6:11-14, the compound of the formula 3 can be prepared

stereospecifically, i.e., so that a Z-isomer and an E-isomer of the compound of the formula 3 are in a ratio of about 8.1-15.7:1.0 which can be seen from Table 1 of the following Examples, and the compounds of the formulae 1 and 3 can be prepared in high yield and purity. In particular, when the volume ratio of water, isopropanol, and methylenechloride in the mixed solvent is 1:4:12, the Z/E isomers with high ratio of Z/E can be obtained in high yield.

In preparation of the compound of the formula 3, the mixed solvent may be used in an amount of about 5-20 times by weight, and preferably about 10-15 times by weight, based on the compound of the formula 4. Acetaldehyde may be used in an amount of about 5-30 equivalents (eq.), and preferably about 10-15 eq., based on 1 eq. of the compound of the formula 4. The preparation of the compound of the formula 3 may be performed at a temperature of about -20 to -10°C for about 2 to 20 hours, and preferably about 10 to 15 hours.

The compound of the formula 4 can be prepared according to a known method (e.g., Korean Patent Laid-Open Publication No. 2002-80838). That is, the compound of the formula 4 can be prepared by reacting a 3-halomethyl cephem compound represented by the following formula 5 with triphenylphosphine to obtain a phosphonium salt, followed by treatment with a third base such as sodium hydroxide or sodium carbonate:

<Formula 5>




wherein R² and R³ are as defined in the above and X is a halogen.

The preparation of the compound of the formula 4 and the preparation of the compound of the formula 3 can be performed by one-pot reaction without separately separating the compound of the formula 4. In this case, since the base used in the preparation of the compound of the formula 4 remains in a reaction solution, there is no need to further add a base in a subsequent process, i.e., in the preparation of the compound of the formula 3, which simplifies preparation processes.

The compound of the formula 3 can be converted to 7-amino-3-[propen-1-yl]-3-cephem-4-carboxyl acid represented by the following formula

6 by common protecting group removal:

<Formula 6>




The compound of the formula 2 can be prepared according to a known method
(Korean Patent Laid-Open Publication No. 2002-69437).

Preferably, the compound of the formula 2 is used in an amount of 1 to 3 eq.,
and preferably 1.1 to 1.5 eq., based on 1 eq. of the compound of the formula 3.
Preferably, the reaction of the compound of the formula 2 with the compound of the
formula 3 is performed in a mixed solvent of water with an organic solvent selected
from the group consisting of diethylsulfoxide, dimethylformamide,
diethylacetamide, 1,4-dioxane, acetonitrile, dichloromethane, and a mixture thereof.
At this time, it is preferred that the content of water in the mixed solvent is 0.05 to 0.3
parts by weight, and preferably 0.1 to 0.2 parts by weight, based on 1 part by weight of
the organic solvent. The reaction can be performed at a temperature of -50 to -20°C,
preferably -40 to -30°C, for 1 to 4 hours, preferably 1.5 to 2.5 hours.

Examples of the second base that can be used in the reaction of the compound
of the formula 2 with the compound of the formula 3 include N-methylmorpholine,
triethylamine, diethylamine, n-tributylamine, N,N-dimethylaniline, and pyridine. Among
them, triethylamine is preferred. Preferably, the second base is used in an amount of
about 1.0 to 2.5 eq., preferably 1.1 to 1.5 eq., based on 1 eq. of the compound of the
formula 2.

The entire preparation processes of the present invention can be expressed by
the following reaction scheme 1:

<Reaction Scheme 1>

Effect of the Invention

5 According to the present invention, cephalosporin antibiotics, including cefprozil and its salt, can be easily prepared in high yield and purity using a 3-(Z)-propenyl cephem derivative stereospecifically prepared.

BEST MODE FOR CARRYING OUT THE INVENTION

10 Hereinafter, the present invention will be described more specifically by Examples. However, the following Examples are provided only for illustrations and thus the present invention is not limited to or by them.

Example 1: Preparation of

7-phenylacetamido-3-[propen-1-yl]-3-cephem-4-carboxylic acid/p-methoxybenzyl ester

15 16 g of sodium iodide and 28 g of triphenylphosphine were added to a reactor containing 50g (102.7mmol) of 3-chloromethyl-7-phenylacetamido-3-[propen-1-yl]-3-cephem-4-carboxylic acid p-methoxybenzyl ester. 400 ml of methylenechloride was added thereto and stirred at

20°C for 2 hours. After phase separation, 200 ml of a 20% sodium hydroxide solution was dropwise added to an obtained organic layer and stirred at 10°C for 30 minutes. After separation of an organic layer, a phosphoranylidene solution was obtained.

200 ml of methylenechloride, 200 ml of isopropanol, and 50 ml of water were added to the phosphoranylidene solution and cooled to -20°C. 100 ml of acetaldehyde was dropwise added thereto and stirred for 20 hours. 30% potassium thiosulfuric acid was dropwise added and stirred for 30 minutes to separate an organic layer. 200 ml of isopropanol was dropwise added to the obtained organic layer, concentrated to produce a crystal, cooled to 0°C, and stirred for 2 hours to precipitate a solid. The solid was filtered and dried in vacuum to give 42.3g (88.4mmol, yield 86%, Z/E=10.1/1) of the titled compound as a white solid.

H-NMR(δ , DMSO- d_6): 1.52(3Hx10.1/11.1, d, (Z)-CH₃), 1.73(3Hx1.0/11.1, (E)-CH₃), 3.36-3.68(4H, m, phCH₂, C-2), 3.75(3H, s, -OCH₃), 5.06-5.24(3H, m, CO₂-CH₂, C-6), 5.52-5.69(2H, d, -CH=CH(CH₃), 6.06(1H, d, -CH=CH(CH₃), C-7), 6.91(2H, d, ph), 7.19-7.62(7.19-7.62(7H, m, ph)

Example 2: Preparation of 7-amino-3-[propen-1-yl]-3-cephem-4-carboxylic acid

22.8 g of phosphorous pentachloride, 150 ml of methylenechloride, and 8.88 ml of pyridine were added to a 20°C reactor and stirred for 30 minutes. 30 g (62.6 mmol) of the 7-phenylacetamido-3-[propen-1-yl]-3-cephem-4-carboxylic acid p-methoxybenzyl ester prepared in Example 1 was dropwise added thereto, stirred for 2 hours, and cooled to -10°C. The reaction mixture was stirred for 2 hours after addition of 30 ml of 1,2-propanediol and then for 2 hours after addition of 120 ml of cresol. 200 ml of distilled water was dropwise added to the reaction solution and stirred for 1 hour. After phase separation, an aqueous layer was sent to a crystallization bath and an organic layer was extracted with 300 ml of 2N HCl and then the extract was sent to the crystallization bath. 200 ml of a 30% sodium hydroxide solution was dropwise added to the crystallization bath for crystallization and cooled to 0°C to precipitate a solid. The solid was filtered and dried in vacuum to give 12g (50mmol, yield 80%, Z/E=10.1/1) of the titled compound as a beige solid.

H-NMR(δ , D₂O+NaHCO₃): 1.69 and 1.88(3H, each, d, 6.0Hz, -CH=CH-CH₃), 3.38 and 3.72(2H, Abq, 17Hz, H-2), 5.18(1H, d, 5.0Hz, H-6), 5.51(1H, d, H-7), 5.8(1H,

m, -CH=CH-CH₃), 6.06(1H, d, 11Hz, -CH=CH-CH₃)

Example 3: Preparation of 7-[2-amino-2-(4-hydroxyphenyl)acetamido]-3-[propen-1-yl]-3-cephem-4-carboxylic acid (cefprozil)

Step A

75g (0.247mol) of potassium (2-ethoxycarbonyl-1-methyl-vinylamino)-(4-hydroxyphenyl)-acetate, 100 ml of dimethylformamide, and 10 ml of pyridine were added to a reactor and a mixed solution of 35 ml of pivaloyl chloride and 200 ml of methylenechloride was dropwise added thereto. The reaction mixture was stirred at -30°C for 2 hours.

Step B

The reaction solution obtained in step A was cooled to -40°C and then a solution obtained by dissolving 50g (0.208mol) of the 7-amino-3-[propen-1-yl]-3-cephem-4-carboxylic acid prepared in Example 2 in 200 ml of methylenechloride, 50 ml of water, and 6.5 g of triethylamine was slowly dropwise added thereto for 1 hour.

Then, the resultant solution was incubated at the same temperature for 2 hours and set to a temperature of 0°C to obtain an insoluble solid. After the insoluble solid was filtered, a filtrate was sent to a reactor. 100 ml of 6N HCl was added thereto and stirred for 1 hour. The reaction solution was set to a pH of 3.2 by addition of 10% NaOH, stirred at 0°C for 2 hours, and filtered to give 68.9g (0.177mol, 85%) of the titled compound as a white solid.

H-NMR(δ, D₂O-d₂) : 1.65(3H, d, 8.6Hz, -CH=CHCH₃(cis)), 1.81(0.21H, d, 8.6Hz, -CH=CHCH₃(trans)), 3.22(1H, d, 18Hz, 2-H), 3.55(1H, d, 18Hz, 2-H), 5.15(1H, d, 4.6Hz, 6-H), 5.66(1H, d, 4.6Hz, 7-H), 5.75(1H, m, vinyl-H), 5.96(1H, m, vinyl-H), 6.91(2H, d, 8.0Hz, phenyl-H), 7.38(2H, d, 8.0Hz, phenyl-H)

Examples 4 and 5

7-phenylacetamido-3-[propen-1-yl]-3-cephem-4-carboxylic acid p-methoxybenzyl ester was prepared in the same manner as in Example 1 except that the volume ratio of methylenechloride, isopropanol, and water was as listed in Table 1 below. The yields

and Z/E isomer ratios of the compounds of Examples 1, 4, and 5 are summarized in Table 1 below.

Table 1

Section	Methylenechloride (A) (ml)	Isopropanol (B) (ml)	Water (C) (ml)	Solvent ratio (A:B:C)	Yield (%)	Z/E isomer ratio
Example 4	150	150	50	11:3:1	83	8.9/1
Example 1	200	200	50	12:4:1	86	10.1/1
Example 5	300	300	50	14:6:1	85	9.1/1

5

As seen from Table 1, when a mixed solvent including methylenechloride, isopropanol, and water is used according to a solvent ratio as defined in the present invention, a 3-propenyl cephem compound of formula 3 can be stereospecifically prepared in high yield. In particular, when the volume ratio of methylenechloride, isopropanol, and water was 12:4:1, the most excellent results were obtained in terms of yield and purity.





10

CLAIMS

1. A process for preparing a compound represented by the following formula 1 or its salt, which comprises:

5 reacting a compound represented by the following formula 4 with acetaldehyde in a mixed solvent comprising water, isopropanol, and methylenechloride in a volume ratio of 1:3-6:11-14 in the presence of a first base to stereospecifically prepare a compound represented by the following formula 3; and

10 reacting the compound of the formula 3 with an anhydrous compound represented by the following formula 2 in the presence of a second base:



wherein R¹ is a hydrogen or an amino protecting group, R² is a hydrogen or a carboxyl protecting group, and R³ is a hydrogen or an amino protecting group.

2. The process of claim 1, wherein the volume ratio of water, isopropanol, and methylenechloride in the mixed solvent is 1:4:12.

3. The process of claim 1, wherein the compound of the formula 3 reacts with the compound of the formula 2 at an equivalent ratio of 1 to 1.1-1.5.

4. The process of claim 1, wherein the compound of the formula 2 reacts with the compound of the formula 3 in a mixed solvent of water with an organic solvent selected from the group consisting of dimethylsulfoxide, dimethylformamide, dimethylacetamide, 1,4-dioxane, acetonitrile, dichloromethane, and a mixture thereof.

5. The process of claim 4, wherein in the mixed solvent, water is used in an amount of 0.05 to 0.3 parts by weight, based on 1 part by weight of the organic solvent.

6. The process of claim 1, wherein the second base is selected from the group consisting of N-methylmorpholine, triethylamine, diethylamine, n-tributylamine, N,N-dimethylaniline, and pyridine.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR2004/002771

A. CLASSIFICATION OF SUBJECT MATTER**IPC7 C07D 501/22**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 07 C07D 501/22

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Korean Patents and applications for inventions since 1975Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
STN (CA, Registry)**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 02/68428 A1 (HANMI PHARM. CO., LTD.) 6 September 2002 See the whole document	1-6
A	WO 02/83692 A1 (HANMI PHARM. CO., LTD.) 24 October 2002 See the whole document	1-6
A	WO 03/11871 A1 (BIOCHEMIE GESELLSCHAFT M.B.H.) 13 February 2003 See the whole document	1-6
A	TAKAYUKI NAITO, et al., 'Synthesis and Structure-Activity Relationships of a New oral Cephalosporin, BMY-28100 And Related Compounds', The Journal of Antibiotics 1987, Vol.40, No.7, pp.991-1005 See the whole document	1-6
A	US 4699979 A (BRISTOL-MEYERS COMPANY) 13 October 1987 See the whole document	1-6

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

04 FEBRUARY 2005 (04.02.2005)

Date of mailing of the international search report

07 FEBRUARY 2005 (07.02.2005)

Name and mailing address of the ISA/KR



Korean Intellectual Property Office
920 Dunsan-dong, Seo-gu, Daejeon 302-701,
Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

KIM, Hee Jin

Telephone No. 82-42-481-5412



INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR2004/002771

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 02/68428 A1	06.09.2002	US 20020120136 A1	29.08.2002
WO 02/083692 A1	24.10.2002	US 20040132992 A1 EP 1379530 A1	08.07.2004 14.01.2004
WO 03/11871 A2	13.02.2003	US 2004192909 A1 GB 118764 A0 EP 1414827 A2 CA 2454078 AA	30.09.2004 26.09.2001 06.05.2004 13.02.2003
US 4699979 A	13.10.1987	JP 61249989 A2 IT 8620162 A0 GB 8609661 A FR 2580652 A1 DE 3402642 A1	07.11.1986 21.04.1986 29.05.1986 24.10.1986 02.08.1984

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.